SCHEMBL4593996

SCHEMBL4593996

O=C(O)C(=O)CCCCN1CCN(CCO[N+](=O)[O-])CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
PAOX Q6QHF9 1/20 0.38
KDM4E B2RXH2 8/20 0.36
ALDH1A1 P00352 7/20 0.36
TDP1 Q9NUW8 2/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 1/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
MAPK1 P28482 2/20 0.34
CYP1A2 P05177 1/20 0.34
HTR1A P08908 1/20 0.34
HTR7 P34969 1/20 0.34
HRH2 P25021 1/20 0.34
HRH1 P35367 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TMEM97 Q5BJF2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4594578 0.95 SMN1; SMN2 (0.39) MMP2MMP9KDM4EALDH1A1TDP1
SCHEMBL4594020 0.94 PAOX (0.38) MMP2MMP9PAOXKDM4EALDH1A1
SCHEMBL4593885 0.89 SMN1; SMN2 (0.39) MMP2MMP9KDM4EALDH1A1TDP1
SCHEMBL4594077 0.89 KDM4E (0.39) MMP2MMP9KDM4EALDH1A1TDP1
SCHEMBL4593556 0.88 PAOX (0.38) PAOXKDM4EALDH1A1TDP1CYP2D6
SCHEMBL4594912 0.86 ALDH1A1 (0.38) KDM4EALDH1A1TDP1CYP2D6CYP2C19
SCHEMBL4593088 0.83 SMN1; SMN2 (0.39) PAOXKDM4EALDH1A1TDP1CYP2D6
SCHEMBL4586997 0.77 KDM4E (0.40) PAOXKDM4ECYP2D6CYP2C19KMT2A
SCHEMBL4588394 0.76 APEX1 (0.36) KDM4EALDH1A1TDP1MAPTSMN1; SMN2
SCHEMBL14607630 0.76 GNAI3 (0.38) MMP2MMP9ALDH1A1MAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US claimed
EP-1692107-A4 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-10-29 EP claimed
EP-1692107-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2006-08-23 EP claimed
WO-2005060603-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-07-07 WO claimed
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US disclosed
EP-1692107-A4 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-10-29 EP disclosed
EP-1692107-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2006-08-23 EP disclosed
WO-2005060603-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use PC, PDK1, NOS3 MMP2 2437/4885MMP9 1629/4885PAOX 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.